Personalized immunotherapy to fight HIV/AIDS

For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, with ARGOS Therapeutics (North Carolina, US) an industrial partner, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients.